secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011486
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios Q2 net loss $1.0M; Long-COVID Phase 2a data expected Oct 2024
--------------------------------------------------------------------

- Net loss $1.0M ($0.05/sh) vs $1.4M ($0.08/sh) in Q2 2023; revenue was $0.
- Cash $3.0M at June 30, 2024; expects runway into Q1 2025 after $1.7M public offering.
- Enrollment completed in Long-COVID Phase 2a (valacyclovir/celecoxib vs placebo); top-line data October 2024.
- R&D expense fell to $0.3M from $0.6M; G&A fell to $0.7M from $0.9M, both YoY.
- Blinded safety analysis shows no serious adverse events; study drug well tolerated to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024011486/0001558370-24-011486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024011486/viri-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer